Abstract
AIM: This study aimed at developing antibody-functionalized gold nanoparticles (AuNPs) to selectively target cancer cells and probing their potential radiosensitizing effects under proton irradiation.
MATERIALS & METHODS: AuNPs were conjugated with cetuximab (Ctxb-AuNPs). Ctxb-AuNP uptake was evaluated by transmission electron microscopy and atomic absorption spectroscopy. Radioenhancing effect was assessed using conventional clonogenic assay.
RESULTS & CONCLUSION: Ctxb-AuNPs specifically bound to and accumulated in EGFR-overexpressing A431 cells, compared with EGFR-negative MDA-MB-453 cells. Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 317-333 |
| Number of pages | 17 |
| Journal | Nanomedicine |
| Volume | 14 |
| Issue number | 3 |
| Early online date | 2019 |
| DOIs | |
| Publication status | Published - 1 Feb 2019 |
Fingerprint
Keywords
- EGFR
- gold nanoparticles
- nanoparticle uptake
- protontherapy
- radiosentizing effects
Cite this
}
Antibody-functionalized gold nanoparticles as tumor targeting radiosensitizers for proton therapy. / Li, Sha; Bouchy, Sandra; Penninckx, Sebastien; Marega, Riccardo; Fichera, Ornella; Gallez, Bernard; Feron, Olivier; Martinive, Philippe; Heuskin, Anne-Catherine; Michiels, Carine; Lucas, Stéphane.
In: Nanomedicine, Vol. 14, No. 3, 01.02.2019, p. 317-333.Research output: Contribution to journal › Article
TY - JOUR
T1 - Antibody-functionalized gold nanoparticles as tumor targeting radiosensitizers for proton therapy
AU - Li, Sha
AU - Bouchy, Sandra
AU - Penninckx, Sebastien
AU - Marega, Riccardo
AU - Fichera, Ornella
AU - Gallez, Bernard
AU - Feron, Olivier
AU - Martinive, Philippe
AU - Heuskin, Anne-Catherine
AU - Michiels, Carine
AU - Lucas, Stéphane
PY - 2019/2/1
Y1 - 2019/2/1
N2 - AIM: This study aimed at developing antibody-functionalized gold nanoparticles (AuNPs) to selectively target cancer cells and probing their potential radiosensitizing effects under proton irradiation.MATERIALS & METHODS: AuNPs were conjugated with cetuximab (Ctxb-AuNPs). Ctxb-AuNP uptake was evaluated by transmission electron microscopy and atomic absorption spectroscopy. Radioenhancing effect was assessed using conventional clonogenic assay.RESULTS & CONCLUSION: Ctxb-AuNPs specifically bound to and accumulated in EGFR-overexpressing A431 cells, compared with EGFR-negative MDA-MB-453 cells. Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.
AB - AIM: This study aimed at developing antibody-functionalized gold nanoparticles (AuNPs) to selectively target cancer cells and probing their potential radiosensitizing effects under proton irradiation.MATERIALS & METHODS: AuNPs were conjugated with cetuximab (Ctxb-AuNPs). Ctxb-AuNP uptake was evaluated by transmission electron microscopy and atomic absorption spectroscopy. Radioenhancing effect was assessed using conventional clonogenic assay.RESULTS & CONCLUSION: Ctxb-AuNPs specifically bound to and accumulated in EGFR-overexpressing A431 cells, compared with EGFR-negative MDA-MB-453 cells. Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.
KW - EGFR
KW - gold nanoparticles
KW - nanoparticle uptake
KW - protontherapy
KW - radiosentizing effects
UR - http://www.scopus.com/inward/record.url?scp=85061259208&partnerID=8YFLogxK
U2 - 10.2217/nnm-2018-0161
DO - 10.2217/nnm-2018-0161
M3 - Article
C2 - 30675822
VL - 14
SP - 317
EP - 333
JO - Nanomedicine
JF - Nanomedicine
SN - 1743-5889
IS - 3
ER -